These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20604940)

  • 1. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
    Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
    Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.
    Dunn MD; Rossi SL; Carter DM; Vogt MR; Mehlhop E; Diamond MS; Ross TM
    Virol J; 2010 May; 7():95. PubMed ID: 20462412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.
    Tinker JK; Yan J; Knippel RJ; Panayiotou P; Cornell KA
    Toxins (Basel); 2014 Apr; 6(4):1397-418. PubMed ID: 24759174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.
    Martina BE; Koraka P; van den Doel P; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
    Vaccine; 2008 Jan; 26(2):153-7. PubMed ID: 18069096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.
    Zlatkovic J; Stiasny K; Heinz FX
    J Virol; 2011 Mar; 85(5):1994-2003. PubMed ID: 21147919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.
    De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN
    PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.
    Gershoni-Yahalom O; Landes S; Kleiman-Shoval S; Ben-Nathan D; Kam M; Lachmi BE; Khinich Y; Simanov M; Samina I; Eitan A; Cohen IR; Rager-Zisman B; Porgador A
    Immunology; 2010 Aug; 130(4):527-35. PubMed ID: 20331473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.
    Martina BE; van den Doel P; Koraka P; van Amerongen G; Spohn G; Haagmans BL; Provacia LB; Osterhaus AD; Rimmelzwaan GF
    PLoS One; 2011 Apr; 6(4):e18995. PubMed ID: 21541326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
    Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
    Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.
    Schepp-Berglind J; Luo M; Wang D; Wicker JA; Raja NU; Hoel BD; Holman DH; Barrett AD; Dong JY
    Clin Vaccine Immunol; 2007 Sep; 14(9):1117-26. PubMed ID: 17634508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.
    Alonso-Padilla J; de Oya NJ; Blázquez AB; Escribano-Romero E; Escribano JM; Saiz JC
    Vaccine; 2011 Feb; 29(9):1830-5. PubMed ID: 21211580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.